Real-Time Blood Plasma Polymerase Chain Reaction for Management of Disseminated Adenovirus Infection

Leruez-Ville, Marianne; Minard, Véronique; Lacaille, Florence; Buzyn, Agnès; Abachin, Eric; Blanche, Stéphane; Freymuth, François; Rouzioux, Christine
January 2004
Clinical Infectious Diseases;1/1/2004, Vol. 38 Issue 1, p45
Academic Journal
We evaluated the usefulness of quantifying blood plasma adenovirus DNA loads for the management of adenovirus infection. Quantification of adenovirus A, B, and C DNA loads was done with real-time polymerase chain reaction (PCR) assays. Blood plasma specimens obtained from 44 immunocompromised patients were screened prospectively with this method. PCR findings for 36 patients were negative, and none of the patients developed disseminated adenoviral disease. PCR findings for 8 patients were positive; all 8 had invasive adenoviral disease and were treated with cidofovir. Sequential measurements of adenovirus DNA loads were performed to monitor the effect of cidofovir therapy. Decrease in the blood plasma DNA load was significantly higher in patients with a good response to cidofovir than in patients with a poor response and was therefore correlated with survival. Detection of adenovirus DNA in blood plasma appears to be useful for identifying patients at risk for invasive disease. Moreover, quantification of adenovirus DNA loads in plasma is helpful for monitoring the efficacy of antiviral therapy.


Related Articles

  • Development of Herpes Simplex Virus Disease in Patients Who Are Receiving Cidofovir. Wyles, David L.; Patel, Amita; Madinger, Nancy; Bessesen, Mary; Krause, Philip R.; Weinberg, Adriana // Clinical Infectious Diseases;9/1/2005, Vol. 41 Issue 5, p676 

    Background. Cidofovir is a nucleotide analogue with antiviral activity against a wide range of DNA viruses, including herpes simplex virus (HSV). In vitro resistance to cidofovir has been reported with use of laboratory HSV strains; clinical failure of cidofovir therapy for HSV disease has also...

  • Human papillomavirus (HPV) detected in restored plasma DNA from women diagnosed with pre-invasive lesions and invasive cervical cancer. ARIAS, YAZMÍN ROCÍO; CARRILLO, EDWARD FABIÁN; ARISTIZÁBAL, FABIO ANCÍZAR // Colombia Medica;abr-jun2010, Vol. 41 Issue 2, p148 

    Objective: To improve the sensitivity of Human Papillomavirus (HPV) detection in plasma from high-grade cervical neoplasia patients (CIN III) and cervical cancer (CC) evaluating any likely correlation with disease stage. Method: We subjected plasma DNA isolates from 112 patients (CIN and ICC) to...

  • The BK virus in renal transplant recipients-review of pathogenesis, diagnosis, and treatment. Dharnidharka, Vikas; Abdulnour, Husam; Araya, Carlos // Pediatric Nephrology;Oct2011, Vol. 26 Issue 10, p1763 

    The BK virus, a DNA virus from the Polyomavirus group, represents an opportunistic infection of immunosuppressed transplant recipients. Though the virus was discovered approximately 40 years ago, the emergence of BK virus nephropathy since 1995 onwards, with associated high graft loss rates, has...

  • Application of Bioinformatics for the Search of Novel Anti-Viral Therapies: Rational Design of Anti-Herpes Agents. Speck-Planche, Alejandro; Cordeiro, M. Natália D. S. // Current Bioinformatics;Mar2011, Vol. 6 Issue 1, p81 

    Human herpes viruses (HHV) are leading cause of human viral diseases, second after influenza and cold viruses. They cause overt disease or can remain silent for many years waiting for reactivation. HHV are associated to several side-effects or co-conditions like Alzheimer's disease,...

  • Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials. Gupta, Ravindra; Hill, Andrew; Sawyer, Anthony W.; Pillay, Deenan // Clinical Infectious Diseases;9/1/2008, Vol. 47 Issue 5, p712 

    Background. Resistance to antiretroviral combination therapy is associated with increased mortality. Understanding the relative risks of emerging resistance to first-line therapy is of importance for both resource-rich and resource-poor settings. Methods. We undertook an overview of clinical...

  • Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice. Farrell, RA; Espasandin, M; Lakdawala, N; Creeke, PI; Worthington, V; Giovannoni, G // Multiple Sclerosis Journal;Nov2011, Vol. 17 Issue 11, p1333 

    Background: Incorporation of routine clinical testing for neutralizing antibodies (NAbs) to interferon (IFN)-β has remained problematic. With increasing treatment choice for patients, routine NAb testing should be incorporated to aid therapeutic decisions.Objective: We sought to improve...

  • Optimal Design of Intervention Studies to Prevent Influenza in Healthy Cohorts. Klick, Brendan; Nishiura, Hiroshi; Cowling, Benjamin J. // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Background: Influenza cohort studies, in which participants are monitored for infection over an epidemic period, are invaluable in assessing the effectiveness of control measures such as vaccination, antiviral prophylaxis and nonpharmaceutical interventions (NPIs). Influenza infections and...

  • First isolation of Rickettsia conorii from humans in the Trakya (European) region of Turkey. Kuloglu, F.; Rolain, J. M.; Fournier, P. E.; Akata, F.; Tugrul, M.; Raoult, D. // European Journal of Clinical Microbiology & Infectious Diseases;Aug2004, Vol. 23 Issue 8, p609 

    In the Trakya region of Turkey, located in the European part of the country, presumptive cases of Mediterranean spotted fever have been diagnosed and treated every summer since the beginning of the 1990s. The aim of this prospective study was to isolate and identify the rickettsial strains from...

  • Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma. FEI-PENG ZHAO; XIONG LIU; XIAO-MEI CHEN; JUAN LU; BO-LONG YU; WEN-DONG TIAN; LU WANG; XIA XU; HAO-RAN HUANG; MENG-WEN ZHANG; GANG LI; XIANG-PING LI // Oncology Letters;Nov2015, Vol. 10 Issue 5, p2888 

    The level of Epstein-Barr virus DNA (EBV-DNA) in the plasma prior and subsequent to treatment is a reliable biomarker for the screening, diagnosis, monitoring and prognosis of nasopharyngeal carcinoma (NPC). The present retrospective study aimed to determine whether pre- and post-treatment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics